Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Can Merck Beat Pfizer in This Multibillion-Dollar Vaccine Market?
Can Merck Beat Pfizer in This Multibillion-Dollar Vaccine Market?
Can Merck Beat Pfizer in This Multibillion-Dollar Vaccine Market?
Submitted by
admin
on August 1, 2021 - 11:50pm
Source:
Motley Fool
News Tags:
Merck
Pfizer
vaccines
Vaxneuvance
Prevnar 20
pneumococcal disease
Headline:
Can Merck Beat Pfizer in This Multibillion-Dollar Vaccine Market?
snippet:
Merck and Pfizer are poised to go head-to-head in a vaccine market that Pfizer has dominated for a while.
Pfizer has a new vaccine that should enable it to prevail over Merck in the adult market.
But Merck has a head start over Pfizer in the large pediatric vaccine market.
Do Not Allow Advertisers to Use My Personal information